Skip to navigation Skip to content

Clinical Trial: Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program

Share

Details
Type of MS: RRMS
Treatment mode of action: To affect immune function
Number of Subjects: 15
Medication: Plegridy (peginterferon β-1a)
Location: New York
Institutions:

Neurological Associates of Long Island, 1991 Marcus Ave Suite 110 Lake Success, NY 11042

Contact Information
Stella Gurgova, ext. 140
516-466-4700
sgurgova@neuroli.com

Funding:

Biogen

Description

The purpose of this observational study is to find out more about the long-term safety and effectiveness of Plegridy, over approximately a five-year time period. Information on side effects (for example, flu-like symptoms [FLS], injection site reactions [ISRs], and other serious side effects), relapses, disability progression, and the quality of life in patients taking Plegridy will be collected. You do not need to come to the clinic for any extra visits as you will see your doctor as part of your regular care. Your participation in the study is voluntary.

Study Site
Neurological Associates of Long Island, PC, 1991 Marcus Ave Suite 110 Lake Success, NY 11042

Share